IV Chelation in Spain: Prices, Protocol & Specialised Clinics

IV chelation is a medical treatment that intravenously administers chelating agents (primarily EDTA — ethylenediaminetetraacetic acid — and DMPS) that bind to heavy metals (lead, mercury, arsenic, cadmium) and eliminate them via the kidneys. In functional cardiology, EDTA is also used to reduce calcium deposits in arterial walls, with evidence from the NIH's TACT trial for reducing cardiovascular events.

Origin and history

EDTA was synthesised in Germany in the 1930s. Its medical use for lead poisoning was established in the 1950s. Dr Norman Clarke introduced its cardiovascular use in 1956. Despite initial controversy, the TACT trial (2002–2012) provided grade A evidence for its use in functional cardiology.

1. Heavy metal analysis Provoked urine with oral DMSA or blood test. Baseline zinc, calcium and magnesium levels.

2. Formulation and premedication Pre-infusion supplementation with essential minerals: zinc, magnesium, oral calcium.

3. EDTA IV infusion Ca-Na₂ EDTA in saline. 1.5–3 g over 3–4 hours. Maximum rate: 1 g/h.

4. Monitoring during infusion Calcium and symptom monitoring. Rate adjustment based on tolerance.

5. Periodic blood work Heavy metal panel, renal function and electrolytes every 5 sessions.

• Removal of bioaccumulated heavy metals (lead, mercury, arsenic)
• Reduction of cardiovascular events in post-MI patients (TACT trial)
• Improved endothelial function
• Reduction of metal-induced oxidative stress
• Support for neurodegenerative diseases with a toxic component
• Improved peripheral circulation

• 1People with confirmed heavy metal exposure
• 2Post-MI patients (especially diabetics)
• 3People with peripheral arterial disease
• 4Those seeking deep detoxification after industrial or environmental exposure
• 5People with symptoms of chronic metal toxicity

• Renal insufficiency (EDTA is renally eliminated)
• Pregnancy
• Hypocalcaemia (EDTA chelates calcium)
• Severe zinc deficiency (EDTA also chelates zinc)

Clinics on LongevityMap declare their exact equipment for objective scoring.

€100–200 per infusion

20–40 infusions in initial protocol (1–2/week)

Prices vary by clinic, equipment and practitioner experience. LongevityMap compares price and quality so you always make the best decision.

The TACT trial (Trial to Assess Chelation Therapy) by the NIH, published in JAMA (2013) with 1,708 post-MI patients, showed an 18% reduction in cardiovascular events with EDTA chelation versus placebo. In diabetic post-MI patients, the reduction was 41%. Mechanisms include reduction of metal-catalysed oxidative stress and improved endothelial function.